Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: The ECOG 3598 study

Journal of Clinical Oncology

Volumn 30, Issue 6, 2012, Pages 616-622

  Hoang, Tien ^a   Dahlberg, Suzanne E ^b   Schiller, Joan H ^a   Mehta, Minesh P ^a   Fitzgerald, Thomas J ^c   Belinsky, Steven A ^d   Johnson, David H ^e  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Quality Assurance Review Center   (United States)

^d LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARBOPLATIN; PACLITAXEL; THALIDOMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONSCIOUSNESS; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; HYPOXIA; INTESTINE FISTULA; LEUKOPENIA; LOADING DRUG DOSE; LUNG FIBROSIS; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; TREMOR; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM MICROMETASTASIS; NEOPLASM STAGING; PACLITAXEL; SURVIVAL RATE; THALIDOMIDE; THROMBOEMBOLISM;

EID: 84863116718     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.9116     Document Type: Article

References (20)

1. Dillman RO, Herndon J, Seagren SL, et al: Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996 (Pubitemid 26302034)
2. Sause W, Kolesar P, Taylor S IV, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117: 358-364, 2000 (Pubitemid 30111583)
3. Furuse K, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999 (Pubitemid 29415225)
4. Curran WJ, Scott CB, Langer CJ, et al: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG 9410. Proc Am Soc Clin Oncol 22, 2003 (suppl; abstr 2499)
5. Zatloukal P, Petruzelka L, Zemanova M, et al: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. Lung Cancer 46:87-98, 2004 (Pubitemid 39201387)
6. Fournel P, Robinet G, Thomas P, et al: Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol 23:5910-5917, 2005
7. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085, 1994 (Pubitemid 24139577)
8. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979 (Pubitemid 10242750)
9. Jennison C, Turnbull B: Interim analyses: The repeated confidence interval approach (with discussion). JR Stat Soc 51:305-361, 1989
10. Lyman GH, Khorana AA, Falanga A, et al: American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505, 2007 (Pubitemid 350232226)
11. Bonomi P, Kim K, Fairclough D, et al: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623-631, 2000 (Pubitemid 30078543)
12. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
13. Choy H, Akerley W, Safran H, et al: Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16:3316-3322, 1998 (Pubitemid 28481627)
14. Belani C, Aisner J, Day R, et al: Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for lcoally advanced non-small cell lung cancer (NSCLC): Three year follow-up. Proc Am Soc Clin Onc 16, 1997 (suppl; abstr 1608)
15. Lee SM, Rudd R, Woll PJ, et al: Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:5248-5254, 2009
16. Pujol JL, Breton JL, Gervais R, et al: Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: An intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 25:3945-3951, 2007 (Pubitemid 47477272)
17. Lee SM, Woll PJ, Rudd R, et al: Antiangiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: A randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 101:1049-1057, 2009
18. Lu C, Lee JJ, Komaki R, et al: Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: A randomized phase III trial. J Natl Cancer Inst 102:859-865, 2010
19. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
20. Spigel DR, Hainsworth JD, Yardley DA, et al: Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 28:43-48, 2010